Pevonedistat (MLN4924)
目录号:S7109 Purity: 99.99%
Pevonedistat (MLN4924)是Nedd8激活酶(NAE)的小分子抑制剂,IC50为4 nM。
CAS: 905579-51-3
客户使用Selleck的Pevonedistat (MLN4924)发表文献128篇
- Signal Transduct Target Ther, 2024 9(1):65
- Mol Cancer, 2024 23(1):242
- Nat Cell Biol, 2022 24(3):384-399
- Cell, 2021 184(2):334-351.e20
- Cancer Cell, 2020 37(3):371-386
- Cancer Cell, 2019 36(5):498-511
- Nat Med, 2017 23(9):1055-1062
- Nat Struct Mol Biol, 2024 10.1038/s41594-024-01257-y
- Nat Commun, 2024 15(1):10596
- Nat Commun, 2024 15(1):4584
- Nat Commun, 2024 15(1):2485
- EMBO J, 2024 43(6):904-930
- EMBO Rep, 2024 25(9):4033-4061
- Biomed Pharmacother, 2024 180:117606
- PLoS Pathog, 2024 20(12):e1012663
- Cells, 2024 13(19)1609
- Int J Mol Sci, 2024 25(16)8984
- J Biol Chem, 2024 300(4):107209
- Biomedicines, 2024 12(4)755
- Gene, 2024 893:147935
- bioRxiv, 2024 2024.10.12.618026
- Cancer Res Commun, 2024 4(3):834-848
- Biochem Biophys Rep, 2024 37:101650
- bioRxiv, 2024 2024.01.03.574002
- Mol Cell, 2023 10.1016/j.molcel.2023.10.011
- Mol Cell, 2023 83(1):57-73.e9
- Adv Sci (Weinh), 2023 10(3):e2203718
- Proc Natl Acad Sci U S A, 2023 120(39):e2305092120
- Clin Transl Med, 2023 13(5):e1267
- Int J Biol Sci, 2023 19(2):377-392
- Cell Death Dis, 2023 14(7):438
- Cell Rep, 2023 42(1):112002
- J Med Chem, 2023 66(7):4703-4733
- mBio, 2023 10.1128/mbio.00387-23
- iScience, 2023 26(5):106601
- Int J Mol Sci, 2023 24(16)12981
- J Biol Chem, 2023 299(3):102909
- J Biol Chem, 2023 S0021-9258(23)00235-1
- Exp Hematol Oncol, 2023 12(1):77
- PLoS One, 2023 18(2):e0277310
- Med Oncol, 2023 10.1007/s12032-023-02162-y
- Sci Adv, 2023 9(25):eade7890
- bioRxiv, 2023 2023.03.28.534572
- Cancer Res Commun, 2023 3(2):245-257
- Mol Cell, 2022 S1097-2765(22)00661-X
- J Am Chem Soc, 2022 144(12):5594-5605
- Nucleic Acids Res, 2022 50(19):10929-10946
- Blood Cancer J, 2022 12(3):39
- Redox Biol, 2022 51:102291
- Cell Death Dis, 2022 13(10):844
- Cell Death Dis, 2022 13(4):350
- Mol Ther Nucleic Acids, 2022 30:66-79
- Cell Rep, 2022 39(2):110690
- Cell Rep, 2022 38(9):110460
- Cell Rep, 2022 38(12):110538
- J Med Chem, 2022 65(15):10611-10625
- J Med Chem, 2022 65(6):5057-5071
- J Med Chem, 2022 65(6):4709-4726
- Eur J Med Chem, 2022 238:114455
- Mol Cancer Ther, 2022 21(11):1632-1644
- Mol Cancer Ther, 2022 molcanther.0835.2021
- Int Immunopharmacol, 2022 113(Pt A):109329
- J Virol, 2022 96(13):e0071422
- Pharmaceuticals (Basel), 2022 15(2)241
- Oncol Rep, 2022 48(5)201
- ACS Chem Biol, 2022 17(7):1789-1798
- Sci Adv, 2022 8(49):eabq0648
- Nat Commun, 2021 12(1):5263
- J Extracell Vesicles, 2021 10(12):e12153
- ADVANCED SCIENCE, 2021 8(14)
- Adv Sci (Weinh), 2021 e2004846
- J Am Chem Soc, 2021 143(19):7380-7387
- Nucleic Acids Res, 2021 49(2):969-985
- Cancer Res, 2021 81(22):5652-5665
- Sci China Life Sci, 2021 10.1007/s11427-020-1860-2
- Cell Death Dis, 2021 12(9):836
- Cell Chem Biol, 2021 S2451-9456(21)00393-7
- Cell Chem Biol, 2021 28(5):648-661.e5
- J Med Chem, 2021 64(16):12273-12285
- Front Cell Dev Biol, 2021 9:684885
- Eur J Med Chem, 2021 218:113328
- mBio, 2021 12(3):e0100521
- Mol Cancer Ther, 2021 10.1158/1535-7163.MCT-20-0831
- Front Cell Dev Biol, 2021 9:670145
- Pflugers Arch, 2021 473(2):185-196
- PLoS One, 2021 16(10):e0258683
- Exp Cell Res, 2021 403(2):112614
- Sci Adv, 2021 7(32)eabf7561
- J Int Med Res, 2021 49(6):3000605211018592
- ACS Cent Sci, 2020 6(8):1367-1375
- Adv Sci (Weinh), 2020 7(21):2001018
- Nat Chem Biol, 2020 10.1038/s41589-020-0594-x
- Cell Death Differ, 2020 10.1038/s41418-020-00689-5
- Proc Natl Acad Sci U S A, 2020 18;202000848
- Elife, 2020 9e59994
- Mol Oncol, 2020 14(1):105-128
- Biochem Pharmacol, 2020 114122
- Front Cell Dev Biol, 2020 8:605989
- Cancer Biol Med, 2020 17(2):357-370
- Transl Oncol, 2020 13(11):100834
- Neoplasia, 2020 10;22(2):111-119
- Sci Rep, 2020 10(1):15543
- Sci Rep, 2020 10(1):5178
- Cell Cycle, 2020 19;1-12
- Mol Cell, 2019 75(4):849-858
- J Clin Invest, 2019 129(3):972-987
- Cell Death Dis, 2019 10(11):815
- Cell Rep, 2019 28(3):735-745
- Cell Chem Biol, 2019 10.1016/j
- Cell Chem Biol, 2019 10.1016/j.chembiol.2019.11.004
- Oxid Med Cell Longev, 2019 2019:7283639
- Front Immunol, 2019 10:1432
- Cancers (Basel), 2019 11(12)
- Oncol Rep, 2019 41(6):3257-3269
- Sci Adv, 2019 5(2):eaau7130
- Nat Commun, 2018 9(1):2678
- Leukemia, 2018 10.1038/s41375-018-0205-y
- J Exp Clin Cancer Res, 2018 37(1):165
- Cell Rep, 2018 24(2):463-478
- J Immunol, 2018 201(3):930-939
- Cell Cycle, 2018 17(16):2069-2079
- J Biol Chem, 2017 292(9):3683-3691
- Sci Rep, 2017 7(1):5599
- Exp Cell Res, 2017 358(2):234-241
- Stem Cell Reports, 2016 7(6):1140-1151
- Oncotarget, 2016 7(3):3520-32
- Oncotarget, 2016 7(29):45263-45274
- J Immunol, 2016 196(7):3117-23
化学信息&溶解度
分子量 | 443.52 |
分子式 | C21H25N5O4S |
CAS号 | 905579-51-3 |
Smiles | C1CC2=CC=CC=C2C1NC3=C4C=CN(C4=NC=N3)C5CC(C(C5)O)COS(=O)(=O)N |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 89 mg/mL ( 200.66 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 22 mg/mL Water : Insoluble DMSO : 89 mg/mL ( 200.66 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 89 mg/mL Water : Insoluble DMSO : 89 mg/mL ( 200.66 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 89 mg/mL Water : Insoluble DMSO : 88 mg/mL ( 198.41 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 88 mg/mL Water : Insoluble DMSO : 89 mg/mL ( 200.66 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 45 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5% DMSO
30% PEG 300
5% Tween 80
ddH2O
浓度:4mg/ml
(9.02mM)
操作示例:以 1 mL 工作液为例,取50 μL 80 mg/ml的澄清DMSO储备液加到300 μL PEG300中,混合均匀使其澄清;向上述体系中加入50 μL Tween-80,混合均匀使其澄清;然后继续加入600 μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。